Bright Minds Biosciences (DRUG) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $490.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | MPLT |
|---|---|---|
| Share price | $54.05 | $8.83 |
| Market cap | $533.15M | $490.73M |
| 1-day change | +3.94% | -3.50% |
| YTD return | -30.74% | -49.73% |
| 1-year return | -11.99% | — |
| 5-year return | +45.49% | — |
| EPS (TTM) | $-2.05 | $-6.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $40.43 |
| 52-week low | $47.23 | $8.71 |
| Distance from 52-week high | -56.32% | -78.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +181.17% | +200.57% |
| Average volume | 159.01K | 851.70K |
| Shares outstanding | 9.86M | 52.85M |
| Employees | 26 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
DRUG vs MPLT FAQ
Which is bigger, Bright Minds Biosciences or MapLight Therapeutics?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $490.73M for MapLight Therapeutics (MPLT).
Are Bright Minds Biosciences and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.